Research

Mixed

GLP-1 receptor agonists (semaglutide, tirzepatide) produce significant weight loss (10-21%) but also reduce lean body mass, necessitating resistance training to preserve muscle and performance in physically active individuals.

If you are using GLP-1 agonists like semaglutide or tirzepatide for weight loss, expect to lose both fat and some muscle. To protect your strength and athletic performance, you must incorporate resistance training into your routine. This combination helps offset the lean mass loss associated with these drugs. Do not rely on the medication alone; long-term maintenance requires continuous therapy and lifestyle adherence, as stopping treatment typically leads to weight regain.

GoodQualifiesHIGH confidence
Extensive clinical trials have reported reductions in lean body mass while undergoing semaglutide therapy... Including resistance training or regular physical activity in the therapeutic approach may help offset this effect.
Bartosz Skorupski et al. · International Journal of Innovative Technologies in Social Science · 2025

Why this rating

Based on multiple meta-analyses and large clinical trials (SURMOUNT, STEP) cited in the text.

Source

NEXT-GENERATION GLP-1 PHARMACOTHERAPY: ADVANCES IN OBESITY TREATMENT WITH CONSIDERATIONS FOR PHYSICAL PERFORMANCE AND POPULATION HEALTH

Bartosz Skorupski et al. · International Journal of Innovative Technologies in Social Science · 2025

narrative_review
Read the paper

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →